COVID-19患者におけるパクスロビッド（市販薬）の効果に関する研究

基本情報

NCT ID

NCT05263908

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

3,346

治験依頼者名

Pfizer

概要

The purpose of this post marketing observational study is to learn about the safety and effects of the commercial medicine (called PAXLOVID) for the treatment of COVID-19. This study is intended to be registered with the participants who: * Have taken PAXLOVID PACK and have no history of using this medicine. * Are 12 years and older All participants will receive PAXLOVID, a standard treatment for COVID-19. Participants will take PAXLOVID 2 times a day by mouth or as prescribed. We will examine the experiences of people taking PAXLOVID. This will help us determine if PAXLOVID is safe and effective. Participants will be followed up for 28 days after taking PAXLOVID. During this time, participants will be closely watched for the safety and effects of PAXLOVID.

対象疾患

介入

依頼者（Sponsor）

実施施設 (2)